These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 30122306)
1. Semaglutide and GLP-1 analogues as weight-loss agents. Kluger AY; McCullough PA Lancet; 2018 Aug; 392(10148):615-616. PubMed ID: 30122306 [No Abstract] [Full Text] [Related]
2. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Trujillo JM; Nuffer W Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096 [TBL] [Abstract][Full Text] [Related]
3. Acute gastric dilation associated with the use of semaglutide, a GLP-1 analogue. Sanz Segura P; Arguedas Lázaro Y; Mostacero Tapia S; Nerín de la Puerta JM; Sebastián Domingo JJ Gastroenterol Hepatol; 2022 Apr; 45 Suppl 1():125-126. PubMed ID: 33545249 [No Abstract] [Full Text] [Related]
4. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797 [TBL] [Abstract][Full Text] [Related]
5. Oral GLP-1 Analog for Type 2 Diabetes on the Horizon. Abbasi J JAMA; 2018 Aug; 320(6):539. PubMed ID: 30120456 [No Abstract] [Full Text] [Related]
6. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety and benefits of GLP-1 receptor agonists. Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093 [TBL] [Abstract][Full Text] [Related]
9. Semaglutide: a promising new glucagon-like peptide-1 receptor agonist. Scheen AJ Lancet Diabetes Endocrinol; 2017 Apr; 5(4):236-238. PubMed ID: 28110912 [No Abstract] [Full Text] [Related]
10. Once-weekly glucagon-like peptide 1 receptor agonists. Kalra S; Gupta Y J Pak Med Assoc; 2015 Jul; 65(7):796-8. PubMed ID: 26160096 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659 [TBL] [Abstract][Full Text] [Related]
13. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. Zoicas F; Droste M; Mayr B; Buchfelder M; Schöfl C Eur J Endocrinol; 2013 May; 168(5):699-706. PubMed ID: 23392214 [TBL] [Abstract][Full Text] [Related]
15. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Lorenz M; Evers A; Wagner M Bioorg Med Chem Lett; 2013 Jul; 23(14):4011-8. PubMed ID: 23743288 [TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. Tzefos M; Harris K; Brackett A Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377 [TBL] [Abstract][Full Text] [Related]
17. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction. Pastel E; McCulloch LJ; Ward R; Joshi S; Gooding KM; Shore AC; Kos K Clin Sci (Lond); 2017 Mar; 131(5):343-353. PubMed ID: 28049736 [TBL] [Abstract][Full Text] [Related]
18. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. Lovshin JA Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790 [TBL] [Abstract][Full Text] [Related]
19. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Cuthbertson J; Patterson S; O'Harte FP; Bell PM Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998 [TBL] [Abstract][Full Text] [Related]
20. Treating prediabetes in the obese: are GLP-1 analogues the answer? Farr OM; Mantzoros CS Lancet; 2017 Apr; 389(10077):1371-1372. PubMed ID: 28237265 [No Abstract] [Full Text] [Related] [Next] [New Search]